title: The effect of short-term glycemic regulation with gliclazide and metformin on postprandial lipemia.
abstract: OBJECTIVE
  Exaggerated postprandial lipemia is now accepted as an independent risk factor in atherogenesis in type 2 diabetes mellitus. We investigated if better glycemic control improves fasting and postprandial lipid profile in type 2 diabetic patients in the short-term.
  
  
  METHODS
  Thirty-two type 2 diabetic patients were studied before and after desired glycemic regulation with gliclazide and metformin. Basal levels of glucose, total cholesterol, high density lipoprotein, low density lipoprotein, triglyceride, insulin, and C-peptide were evaluated at fasting state. Afterwards, patients were given a standard 400-kcal mixed meal as a breakfast, contaning 35 % fat. At the 2nd and the 4th hours after the breakfast, postprandial glucose, triglyceride, insulin, and C-peptide levels were determined again.
  
  
  RESULTS
  Significant decrease was observed in total cholesterol levels after better glycemic regulation (p<0.05). Besides, triglyceride levels decreased significantly from 175.36+/-17.85 mg/dl to 138.73+/-14.93 mg/dl at fasting state (p<0.05), from 197.26+/-20.85 mg/dl to 154.15+/-14.61 mg/dl at the 2nd hour after mixed meal (p<0.05), and from 209.63+/-28.54 mg/dl to 155.63+/-15.68 mg/dl (p<0.05) at the 4th hour after the mixed meal, when better glycemic profile was provided. Area under curve for triglyceride levels decreased significantly with the better glycemic regulation (p<0.01).
  
  
  CONCLUSIONS
  Improved glycemic regulation can lower the raised fasting and postprandial triglyceride levels which are important atherosclerotic risk factors in diabetic patients even in short-term. Since this improvement in triglyceride levels comes early, diabetic patients can be evaluated for fasting and postprandial triglyceride levels in the first month of therapy.
authors.affiliation: Ankara University, School of Medicine, Department of Endocrinology and Metabolic Diseases, Ankara, Turkey. rifatemral@hotmail.com
authors.forename: R
authors.initials: R
authors.lastname: Emral
authors.forename: O
authors.initials: O
authors.lastname: Köseoğlulari
authors.forename: V
authors.initials: V
authors.lastname: Tonyukuk
authors.forename: A R
authors.initials: AR
authors.lastname: Uysal
authors.forename: N
authors.initials: N
authors.lastname: Kamel
authors.forename: D
authors.initials: D
authors.lastname: Corapçioğlu
mesh_terms: D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D005215:Fasting; D005907:Gliclazide / Q000627:therapeutic use*; D006706:Homeostasis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D020738:Leptin / Q000097:blood*; D008687:Metformin / Q000627:therapeutic use*; D019518:Postprandial Period / Q000502:physiology*
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D020738:Leptin; D008687:Metformin; D005907:Gliclazide